- Condition: Femoral Fractures
Intervention: Device: EBA2
Sponsors: Citieffe S.r.l; Citieffe S.r.l; Opera Srl
Recruiting - verified May 2012 - Condition: Branch Retinal Vein Occlusion
Interventions: Drug: Ranibizumab; Procedure: Laser
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified May 2012 - Condition: Rheumatoid Arthritis
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Breast Cancer
Interventions: Drug: pertuzumab; Drug: trastuzumab; Drug: Aromatase Inhibitor; Drug: Induction Chemotherapy
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Conditions: Acute Promyelocytic Leukemia Female Patients; Pregnancy
Intervention:
Sponsors: Gruppo Italiano Malattie EMatologiche dell'Adulto; Gruppo Italiano Malattie EMatologiche dell'Adulto
Recruiting - verified May 2012 - Condition: Multiple Myeloma
Interventions: Biological: Elotuzumab; Drug: Bortezomib; Drug: Dexamethasone; Drug: Dexamethasone; Drug: Dexamethasone; Drug: Dexamethasone
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Abbott Biotherapeutics Corp.
Recruiting - verified February 2012 - Condition: Leukemia, Pediatric
Intervention: Drug: Dasatinib
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Children's Oncology Group; EsPhALL - European Intergroup Study on Post Induction Treatment of Philadelphia Positive Acute Lymphoblastic Leukaemia with Imatinib
Recruiting - verified April 2012 - Condition: Non-Hodgkin's Lymphoma
Interventions: Drug: rituximab [MabThera/Rituxan]; Drug: rituximab [MabThera/Rituxan]; Drug: rituximab [MabThera/Rituxan]; Drug: chemotherapy
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Hepatitis C, Chronic
Intervention:
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Conditions: Acute Coronary Syndromes; STEMI; NSTEMI
Interventions: Other: trans-radial and short-term bivalirudin; Other: trans-radial and long-term bivalirudin infusion; Other: trans-radial and standard of care pharmacology; Other: Trans-femoral and Short-term bivalirudin; Other: trans-femoral and long-term bivalirudin infusion; Other: trans-femoral and standard of care pharmacology
Sponsors: Italian Society of Invasive Cardiology; Italian Society of Invasive Cardiology; Eustrategy
Recruiting - verified May 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo matching with Saxagliptin; Drug: Metformin IR; Drug: Metformin XR; Drug: Saxagliptin; Drug: Saxagliptin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; AstraZeneca
Not yet recruiting - verified February 2012 - Conditions: Idiopathic Growth Hormone Deficiency; Turner Syndrome
Intervention: Other: Blood sampling
Sponsors: Merck KGaA; Merck KGaA; Merck Serono S.A., Geneva
Recruiting - verified May 2012 - Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: ocrelizumab; Drug: Rebif; Drug: ocrelizumab placebo; Drug: Rebif placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Hepatitis C, Chronic
Interventions: Drug: BI201335; Drug: BI201335 24W; Drug: PegIFN/RBV; Drug: PegIFN/RBV
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Conditions: Multiple Sclerosis; Neurodegenerative Diseases
Intervention:
Sponsors: Fondazione Italiana Sclerosi Multipla; Fondazione Italiana Sclerosi Multipla; Opera Srl
Recruiting - verified April 2012 - Condition: ALL Ph Positive
Intervention: Other: Total therapy approach
Sponsors: Gruppo Italiano Malattie EMatologiche dell'Adulto; Gruppo Italiano Malattie EMatologiche dell'Adulto
Recruiting - verified May 2012 - Condition: Edentulism
Intervention: Device: OsseoSpeed TX
Sponsors: Astra Tech AB; Astra Tech AB
Recruiting - verified April 2012 - Condition: Allergy
Interventions: Dietary Supplement: VSL#3 probiotic preparation; Other: Placebo VSL#3
Sponsors: Policlinico Hospital; Policlinico Hospital
Recruiting - verified May 2012 - Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide; Drug: Dexamethasone; Drug: Dexamethasone; Drug: Dexamethasone; Drug: Dexamethasone; Biological: Elotuzumab (BMS-901608; HuLuc63); Biological: Elotuzumab (BMS-901608; HuLuc63)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Abbott Biotherapeutics Corp.
Recruiting - verified October 2011 - Condition: Malignant Melanoma
Intervention: Drug: RO5185426
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Rheumatoid Arthritis
Interventions: Drug: tocilizumab [RoActemra/Actemra]; Drug: adalimumab; Drug: Placebo; Drug: Placebo; Drug: methotrexate; Drug: folate
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Prostate Cancer Metastatic
Intervention: Drug: CABAZITAXEL
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Condition: Polycythemia Vera
Interventions: Drug: INC424 tablets; Other: Best Available Therapy (BAT)
Sponsors: Incyte Corporation; Incyte Corporation; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Conditions: Carcinoma; Hepatocellular
Intervention: Drug: LY2157299
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified April 2012 - Condition: Schizophrenia
Interventions: Drug: RO4917838; Drug: RO4917838; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Type 2 Diabetes
Interventions: Drug: Saxagliptin; Drug: Placebo (Saxagliptin); Drug: Metformin IR; Drug: Placebo (Metformin); Drug: Metformin (Active Rescue)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; AstraZeneca
Recruiting - verified February 2012 - Condition: Schizophrenia
Interventions: Drug: RO4917838; Drug: RO4917838; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012 - Condition: Primary Myelofibrosis
Interventions: Drug: Pomalidomide; Other: Placebo
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified May 2012 - Condition: Leukemia
Interventions: Drug: asparaginase; Drug: cyclophosphamide; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: ifosfamide; Drug: mercaptopurine; Drug: methotrexate; Drug: methylprednisolone; Drug: prednisone; Drug: thioguanine; Drug: vincristine sulfate; Drug: vindesine
Sponsors: Gruppo Italiano Malattie EMatologiche dell'Adulto; Gruppo Italiano Malattie EMatologiche dell'Adulto
Recruiting - verified May 2012 - Condition: Leukemia
Interventions: Drug: cytarabine; Drug: etoposide; Drug: everolimus; Drug: idarubicin; Drug: mitoxantrone hydrochloride
Sponsors: Gruppo Italiano Malattie EMatologiche dell'Adulto; Gruppo Italiano Malattie EMatologiche dell'Adulto
Recruiting - verified May 2012 - Condition: Acute Coronary Syndrome
Interventions: Drug: Otamixaban (XRP0673); Drug: Otamixaban matching placebo; Drug: Unfractionated Heparin; Drug: Unfractionated Heparin matching placebo; Drug: Eptifibatide; Drug: Eptifibatide matching placebo
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012 - Condition: Breast Cancer
Interventions: Drug: Placebo; Drug: Denosumab
Sponsors: Amgen; Amgen; Daiichi Sankyo Inc.
Recruiting - verified April 2012 - Condition: Leukemia, Myeloid
Intervention: Drug: Nilotinib
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Non-Hodgkin's Lymphoma
Interventions: Drug: bendamustine; Drug: RO5072759
Sponsors: Genentech; Genentech; Roche Pharma AG
Recruiting - verified May 2012 - Condition: Melanoma
Intervention: Drug: nilotinib (AMN107)
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Conditions: Treatment; Stem Cell Transplantation
Interventions: Drug: Nilotinib; Drug: Imatinib
Sponsors: Gruppo Italiano Malattie EMatologiche dell'Adulto; Gruppo Italiano Malattie EMatologiche dell'Adulto
Recruiting - verified May 2012 - Conditions: HER2/Neu Over-expressing Locally Advanced Breast Cancer; Metastatic Breast Cancer
Interventions: Drug: everolimus, vinorelbine, trastuzumab; Drug: Placebo + vinorelbine + trastuzumab
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012 - Conditions: Mantle Cell Lymphoma; Relapsed or Refractory Mantle Cell Lymphoma
Interventions: Drug: Lenalidomide; Drug: Chlorambucil, Rituximab, Cytarabine, Gemcitabine, or Fludarabine
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified May 2012 - Condition: B-cell Chronic Lymphocytic Leukemia
Interventions: Drug: Lenalidomide; Drug: Placebo
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified May 2012 - A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAIONCondition: Optic Neuropathy, Ischemic
Intervention: Drug: No intervention
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Human Immunodeficiency Virus
Interventions: Drug: Maraviroc along with an optimized background antiretroviral drug regimen; Drug: Optimized background antiretroviral drug regimen without maraviroc
Sponsors: ViiV Healthcare; ViiV Healthcare; Pfizer
Recruiting - verified May 2012 - Conditions: β-thalassemia; Transfusional Iron Overload
Intervention: Drug: Deferasirox
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012 - Condition: Neoplasms, Breast
Intervention: Drug: lapatinib + capecitabine
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012
 |
Join Clinical Trials that are held in Bari, Italy |
Clinical Trial Locations 